$NGVT

Ingevity (NGVT) Q2 2026 Earnings Call Transcript

Ingevity (NGVT) held its Q2 2026 earnings call. Net sales were $314 million, down 5% on reported basis due to the Road Markings divestiture. Adjusted EBITDA rose 14% to $115 million, with margin at 36.6%. Adjusted EPS was $1.74. Free cash flow was $89 million. Full-year guidance for EBITDA and EPS was raised.

Original reporting
Published Aug 8, 2026, 2:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 2:39 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ingevity (NGVT) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$NGVTBullishMed
01

Why it matters

Traders should focus on the raised FY2026 EBITDA/EPS/FCF ranges, segment margin drivers (pricing, mix, plant utilization), and the stated demand risks from weaker North America auto production and higher asphalt prices affecting international volumes.

02

Market read

This is a guidance-and-segment-margins update with a new PFAS municipal contract and explicit second-half demand risks, making it actionable for positioning around FY2026 expectations.

03

What to watch

Net leverage is at the upper end of the target range (2.5x), which can constrain flexibility if margins compress or if the Advanced Polymer Technologies divestiture process changes timing.

Relevance 8/10Novelty 8/10Timing: post-earnings call, guidance update for FY2026

Background

The call covers Q2 2026 performance after divesting the Road Markings product line and discusses ongoing progress on the Advanced Polymer Technologies sale process.

Company-level read

Ticker impact

$NGVTBullishMedium confidence
Context

Ingevity reported Q2 results and raised full-year 2026 adjusted EBITDA guidance to $380m-$400m and EPS to $5.00-$5.45.

Expected impact

Bias modestly positive for the next few sessions, with volatility around second-half utilization normalization and guidance sensitivity to auto production.

Evidence & confidence

The article contains multiple fresh, decision-relevant datapoints: Q2 adjusted EBITDA margin expansion, raised full-year EBITDA/EPS/FCF guidance, and a first municipal PFAS filtration contract. Offsetting risks include weaker back-half North America auto production and higher asphalt prices driving delays and international volume declines.

Market effects

Highlights demand tailwinds from hybrid vehicles for carbon solutions and potential resilience in PFAS filtration-related activated carbon applications.

North America auto production weakness in the back half is flagged as a near-term demand cadence risk.

International markets face project delays and volume pressure tied to higher asphalt pricing and China-related declines.

Counterpoint

Guidance raises may be partially offset by second-half utilization normalization and macro-driven project delays, so upside could fade if volumes do not recover as expected.

Key entities

  • Ingevity Corporation

    Reported Q2 2026 results, raised FY2026 guidance, and discussed segment margin expansion and a first municipal PFAS filtration contract.

  • David H. Li

    CEO and President, cited hybrid-vehicle demand and back-half North America auto production weakness.

  • Phillip J. Platt

    CFO, discussed stranded cost elimination and financial drivers behind guidance.

Related articles

$NGVTMedAI 8/10

Ingevity Q2 Earnings Call Highlights

Ingevity (NYSE:NGVT) reported Q2 cash flow excluding a litigation settlement of about $89M, or $2.52/share, with capex near $10M. Performance Materials sales rose 4% to $161M, with segment EBITDA up 6% to $86M and margin to 53.6%. The company raised 2026 outlook to adjusted EBITDA $380M-$400M and EPS $5.00-$5.45, plus free cash flow $220M-$245M.

$NGVTMed

Ingevity Corp (NGVT): Results of Operations and Financial Condition

Ingevity Corp (NGVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Ingevity reports second quarter 2026 financial results Second Quarter 2026 Results and Recent Highlights: • Net sales of $314.1 million decreased 5% from prior year; exc

$IBKRMedAI 8/10

Interactive Brokers Earns Interest on $182 Billion of Its Clients' Idle Cash. Will Anthropic's IPO Drain It?

Interactive Brokers (IBKR) reported $182.4B in uninvested client cash, up 27% YoY, earning interest until invested. Anthropic's potential $2T IPO could impact cash levels, but SpaceX's IPO didn't drain IBKR's reserves. IBKR's Q2 net interest income rose 23% to $1.06B, half of total revenues. Client accounts and trading activity grew, mitigating cash outflows. IBKR stock is near $92, trading at 29x next year's earnings.

$ORCLMedAI 8/10

Oracle’s AI Earnings Story Is Improving, but the Cash Flow Test Remains

Oracle (ORCL) reported strong Q4 earnings with 21% revenue growth and raised its profit forecast. Morgan Stanley increased its price target to $210, citing improved GPUaaS margins. However, the company faces cash flow pressure due to high capital expenditures for AI infrastructure, with free cash flow at negative $23.7 billion. Hedge funds remain invested, with Fisher Asset Management increasing its stake.

$AVGOMedAI 9/10

Broadcom’s AI Forecast Suggests Hyperscalers Want More Than Just Nvidia GPUs

Broadcom (AVGO) raised its AI chip revenue forecast to $115B for FY2027, up from $100B, and expects $230B in FY2028. This reflects Big Tech's demand for custom chips and networking components, reducing reliance on Nvidia (NVDA). KeyBanc reiterated an Overweight rating and $575 price target for AVGO. AVGO's Q3 revenue rose 86% YoY to $29.6B, but Q4 guidance was slightly below expectations. Hedge funds hold positions in both AVGO and NVDA, with Fisher Asset Management among the top holders.